$STE (Steris Plc)

$STE {{ '2016-08-09T18:00:29+0000' | timeago}} • Webcast

$STE said legacy Synergy revenue in constant currency grew low single digits during 1Q17, which is in line with expectations. Gross margin as a percentage of revenue decreased 370 BPs to 38.2%. As expected, Synergy negatively impacted year-over-year gross margin by approx. 500 BPs.

$KAMN {{ '2018-01-10T19:21:07+0000' | timeago}} • Announcement

$KAMN announced that Rebecca F. Stath has been appointed to serve as Assistant Vice President, SEC Compliance and External Reporting, reporting to John J. Tedone, Vice President, Finance and Chief Accounting Officer.

$KAMN {{ '2018-01-10T19:16:01+0000' | timeago}} • Announcement

$KAMN announced that Amanda N. Balboni has been appointed to serve as Assistant Vice President, Internal Audit. Ms. Balboni has previously worked at Coburn Technologies, Stanley Black & Decker and PricewaterhouseCoopers.

$MSA {{ '2018-01-09T19:42:03+0000' | timeago}} • Announcement

$MSA BoD declared 1Q18 dividend of 35 cents per share on common stock. The dividend is payable March 10, 2018 to shareholders of record on February 14, 2018.

$PII {{ '2018-01-09T19:13:23+0000' | timeago}} • Announcement

$PII named Lucy Clark Dougherty as its SVP, General Counsel, Compliance Officer and Corporate Secretary, reporting to Chairman and CEO Scott Wine effective Jan. 29, 2018. Dougherty will also serve as president of the Polaris Foundation.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$AIT {{ '2018-01-09T14:46:20+0000' | timeago}} • Announcement

$AIT has agreed to acquire FCX Performance, Inc. for approx. $768MM. The deal is expected to close within 30 days. The acquisition is expected to contribute about $550MM in sales and $68MM in EBITDA in the first 12 months of applied ownership. The deal is expected to be accretive in FY19 after recognition of one-time transaction costs in FY18.

$CELG {{ '2018-01-08T19:25:23+0000' | timeago}} • Announcement

$CELG announced preliminary results for 4Q17 and FY17. Celgene also provided the outlook for FY18 and reaffirmed FY20 guidance. The company is expected to finalize these results when it announces the earnings results on Jan. 25, 2018.

$CELG {{ '2018-01-08T14:00:46+0000' | timeago}} • Announcement

$CELG agreed to acquire start-up firm Impact Biomedicines for an upfront payment of $1.1Bil. Under the deal terms, Celgene will further pay up to $1.25Bil on Impact's cancer drug Fedratinib getting FDA's approvals. If the global annual net sales of the drug exceed $5Bil, Celgene will pay a maximum of $4.5Bil. The deal is expected to close in 1Q18.

$IART {{ '2018-01-08T12:15:32+0000' | timeago}} • Announcement

$IART said it expects 4Q17 revenue to be approx $365MM, an increase of over 40% compared to 4Q16, helped by Derma Sciences and Codman Neurosurgery acquisitions. The results will be announced in late February, 2018.

$IDXX {{ '2018-01-05T12:52:03+0000' | timeago}} • Announcement

$IDXX expects the recently passed Tax Cuts and Jobs Act to benefit the company by reducing its recurring effective tax rate beginning in 2018, by approx 750-850 bps. It also estimates that the enactment of the tax legislation will result in a one-time reduction of about $35-45MM in earnings for 4Q17 and FY17.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$CELG {{ '2017-12-22T14:11:59+0000' | timeago}} • Announcement

$CELG's cancer drug Revlimid fails to meet the endpoint in the first Phase 3 trial. Celgene said that additional analyses are ongoing and it would present the complete analyzed data in a future medical conference. Revlimid contributed 63% of Celgene's revenue in their recently ended third quarter.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$ABBV {{ '2017-12-21T13:23:43+0000' | timeago}} • Announcement

$ABBV announced positive top-line results from the Phase 3 SELECT-MONOTHERAPY clinical trial. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$ABT {{ '2017-12-15T16:46:17+0000' | timeago}} • Announcement

$ABT increased the company's quarterly common dividend to $0.28 per share from $0.265 per share.  The cash dividend is payable Feb. 15, 2018, to shareholders of record at the close of business on Jan. 12, 2018.

$MSA {{ '2017-12-14T15:07:35+0000' | timeago}} • Announcement

$MSA's BoD has elected Nishan J. Vartanian as a director of the company. Mr. Vartanian currently serves as President and COO. His election is part of a planned management succession, and coincides with an announcement made by Chairman and CEO William M. Lambert that he intends to retire as CEO in May of 2018.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
JCI (Johnson Controls Inc.)
Thursday, November 9 2017 - 4:00pm
SRCL (Stericycle, Inc.)
Wednesday, November 8 2017 - 10:01pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
IVC (Invacare Corporation)
Wednesday, November 8 2017 - 1:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
MTD (Mettler-Toledo International Inc.)
Thursday, November 2 2017 - 9:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, November 2 2017 - 12:00pm
WMGI (Wright Medical Group N.V.)
Wednesday, November 1 2017 - 8:30pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
MASI (Masimo Corporation)
Tuesday, October 31 2017 - 8:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
ABBV (AbbVie Inc.)
Friday, October 27 2017 - 1:00pm
KAMN (Kaman Corporation)
Friday, October 27 2017 - 12:30pm
MTRN (Materion Corporation)
Thursday, October 26 2017 - 1:00pm
CELG (Celgene Corporation)
Thursday, October 26 2017 - 1:00pm

AlphaGraphics you may like